Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synthetic CBD Oil for Mild to Moderate COVID-19
NCT04686539Phase 1Unknown
- Sponsor
- Sheba Medical Center
- Start
- Jan 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Recipients of CBD oil with Recipients of Placebo (2 arms). Primary endpoint: Clinical deterioration at 14 days. Status: unknown.
02
Drugs
cannabidiol
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04686539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04686539.